

Cerveau announces Neuro PET imaging agent test in Singapore

17 December 2018 | News

Cerveau Technologies, Inc. to support a first clinical study in Asia of a novel biomarker of Alzheimer's disease.



Cerveau Technologies Inc., a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group, has announced that the Memory Aging and Cognition Centre (MACC) at the National University Health System (NUHS) in Singapore has initiated a study with an early stage imaging agent [18F]MK-6240 to be used in Positron Emission Tomography (PET) scans for assessing the level and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer's disease.

As part of the agreement, the Clinical Imaging Research Centre (CIRC) at the National University of Singapore's Yong Loo Lin School of Medicine (NUS Medicine) will collaborate with Cerveau to manufacture and supply the [18F]MK-6240 needed for initiatives in Singapore.